Sector News

Bayer offloads Dr. Scholl’s foot care brand for $585M as major revamp presses on

July 23, 2019
Life sciences

Bayer’s healthcare shake-up just took another big step forward. After selling its Coppertone sun care line, the company has worked up a deal for the Dr. Scholl’s foot care brand.

Private equity firm Yellow Wood Partners agreed to buy Bayer’s Dr. Scholl’s business for $585 million. The products brought in €198 million ($234 million) last year, ranking ninth among Bayer’s consumer health brands.

The deal marks the second planned sale in Bayer’s over-the-counter department as part of a bigger shake-up unveiled in November. Bayer penned a pact in May to sell Coppertone to Nivea maker Beiersdorf for $550 million.

Boston-based Yellow Wood, exclusively focused in the consumer industry, will create a standalone Dr. Scholl’s company with the current Bayer employees. The private investment shop’s portfolio includes Freeman Beauty, which also markets foot care products.

Bayer’s entire consumer franchise has been under pressure lately. In 2018, its sales in the sector dropped 6.3%, mainly on lackluster performance in the U.S. as competition intensifies.

Now that Coppertone and Dr. Scholl’s are off the to-do list, Bayer’s next big hive-off is its animal health unit. The company reportedly approached Eli Lilly’s animal health spinoff Elanco about a potential tie-up, but Elanco may not have enough cash to buy Bayer’s division.

All these sell-offs, along with a cost-saving plan and a layoff round, are part of Bayer’s cash-raising efforts in the wake of its $63 billion Monsanto buy. Bayer plans to channel the freed-up resources into strengthening its pharma business, mainly via external collaborations.

The Monsanto deal—and management’s approach to the mounting Roundup litigation that came along with it—have drawn much criticism from shareholders. Last week, a federal judge rejected Bayer’s request for a retrial in one case, but did slash the damages Bayer owed to $25.27 million from $80.27 million.

Given that Bayer has lost its Roundup lawsuits one after another, Bernstein analysts have argued for the company to consider settling. In a move that suggests a deal may indeed be on the horizon, Bayer hired an independent lawyer to advise it on the Roundup suits, and it set up a special committee to oversee the effort.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend